sur NOVACYT (EPA:ALNOV)
Novacyt anticipates significant growth for 2024
Novacyt, a leading molecular diagnostics company, has announced its preliminary results for 2024. The group's unaudited turnover is estimated at £19.6 million, representing a notable increase of 85% compared to 2023. This increase is mainly attributed to the integration of Yourgene Health.
Yourgene's results, however, show a decline in revenue from non-invasive prenatal screening services. Despite this, the company is showing growth in reproductive health and Ranger consumables. Primer Design has helped stabilize revenue.
Novacyt continues to position itself in the market through the development of new analytical capabilities and new products, while streamlining its operations. The company plans to publish its annual results in April 2025.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NOVACYT